I think there is something to be said about going to early and delivering false hope to suffers, being a small phase 1 trial. I don’t think the responsibility parties we are partnered with would like to be seen to be doing that. You saw the subdued response from Prof. Mather to the results and the patient testimonials.
Associate Professor Susan Mathers commented:
“This study has shown oral Monepantel to be safe and well tolerated by people with MND. Given the promising
findings on preliminary efficacy markers, I look forward to progressing a phase 2 study as soon as possible”
I read quite a bit into this line about looking fwd to starting phase 2 asap.
The Final Charge , Phase I/II MND Results & FDA ODD Approval Catalyst, page-778
Add PAA (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
23.5¢ |
Change
0.010(4.44%) |
Mkt cap ! $91.06M | |||
| Open | High | Low | Value | Volume |
| 22.5¢ | 23.5¢ | 22.5¢ | $106.1K | 463.8K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 20000 | 23.5¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 24.0¢ | 93143 | 4 |
View Market Depth
| Last trade - 13.55pm 17/06/2024 (20 minute delay) ? |
|
|||||
|
Last
23.5¢ |
Change
0.010 ( 4.44 %) |
||||
| Open | High | Low | Volume | ||
| 22.5¢ | 23.5¢ | 22.5¢ | 148270 | ||
| Last updated 13.55pm 17/06/2024 ? | |||||
| PAA (ASX) Chart |
